Zydus Cadila bags approval for Doxepin Hcl
The pharma company has received the approval from US drug authorities.
Ahmedabad, February 27, 2013: Zydus Cadila has secured a tentative approval from the US authorities for the Doxepin Hcl tablets. The company plans to launch the drug in 2020.
According to the company, the estimated sales for the drug stood at US$ 15.5 million and it falls under the neuropsychiatry segment. With this approval from USFDA, the company now has 77 approvals and has filed for 172 ANDAs so far since the commencement of the filing process in FY 2003-04.